Experienced investor and operator focused on growth-stage technology companies, with expertise in scaling product, go-to-market and capital strategy. Brian Distler combines hands-on operating experience with board-level oversight, advising CEOs on customer acquisition, unit economics and fundraising. Frequently active in SaaS and fintech investable opportunities, the profile emphasizes capital allocation, KPIs-driven performance improvement and preparation for late-stage rounds or strategic exit.
Experienced investor and operator focused on growth-stage technology companies, with expertise in scaling product, go-to-market and capital strategy. Brian Distler combines hands-on operating experience with board-level oversight, advising CEOs on customer acquisition, unit economics and fundraising. Frequently active in SaaS and fintech investable opportunities, the profile emphasizes capital allocation, KPIs-driven performance improvement and preparation for late-stage rounds or strategic exit.
Targets growth-stage technology companies, primarily SaaS and fintech, deploying capital to scale repeatable revenue models and optimize unit economics. Investment decisions prioritize KPIs-driven underwriting—CAC/LTV, retention, gross margins—and milestone-based follow-on reserves to preserve capital efficiency. Prefers founder-led teams where operating partnership and board governance can accelerate go-to-market and product scaling. Time horizon focused on late-stage rounds or strategic exits (18–36 months), with a disciplined risk framework that favors predictable revenue, margin expansion, and measurable customer acquisition leverage.
Targets growth-stage technology companies, primarily SaaS and fintech, deploying capital to scale repeatable revenue models and optimize unit economics. Investment decisions prioritize KPIs-driven underwriting—CAC/LTV, retention, gross margins—and milestone-based follow-on reserves to preserve capital efficiency. Prefers founder-led teams where operating partnership and board governance can accelerate go-to-market and product scaling. Time horizon focused on late-stage rounds or strategic exits (18–36 months), with a disciplined risk framework that favors predictable revenue, margin expansion, and measurable customer acquisition leverage.
| Trades 1448 | Longs Won 1119/1448 77% | Profit Factor 19.74 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $248,862.16 |
| Average Win $66,226.67 | Best Trade (Oct 15) $5.83M | Sharpe Ratio -11.84 |
| Average Loss -$11,412.46 | Worst Trade (Oct 16) -$487,949.92 | Z-Score 19.92 (100%) |
| Commissions $0 | Avg. Trade Length 1y 3m 3w 3d | Expectancy $48,586.29 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 24,390 | 21,951 | 19,512 | 17,073 | 14,634 | 12,195 | 9,756 | 7,317 | 4,878 | 2,439 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 2547 25470MAB5 | 12,000 | $6,438 | $6,438 | - | - | - | 0.0 |
AAPL Apple Inc. | 27,220 | $5.33M | $9.4M | - | $4.07M | 76.45% | +0.98% |
ABBV AbbVie Inc. | 2,603 | $418,308.77 | $743,416.8 | - | $325,108.03 | 77.72% | +0.776% |
ABT Abbott Laboratories | 2,475 | $276,274.95 | $260,097.75 | - | -$16,177.2 | -5.86% | +0.392% |
ADX Adams Diversified Equity Fund, Inc. | 8,003 | $204,486 | $205,957.2 | - | $1,471.2 | 0.72% | -0.213% |
ALL Allstate Corporation | 1,013 | $241,001 | $247,126.41 | - | $6,125.41 | 2.54% | +1.818% |
AMAT Applied Materials, Inc. | 301 | $217,656 | $126,817.32 | - | -$90,838.68 | -41.73% | -2.021% |
AMD Advanced Micro Devices, Inc. | 616 | $357,695 | $334,685.13 | - | -$23,009.87 | -6.43% | -3.363% |
AMGN Amgen Inc. | 642 | $226,192.96 | $281,003.4 | - | $54,810.44 | 24.23% | +0.846% |
AMT American Tower Corporation | 1,791 | $389,721.73 | $329,069.38 | - | -$60,652.35 | -15.56% | +1.31% |
AMZN Amazon.com Inc | 10,726 | $1.84M | $2.73M | - | $886,955.42 | 48.09% | -0.047% |
APP AppLovin Corporation Class A Common Stock | 1,035 | $533,263 | $284,894.1 | - | -$248,368.9 | -46.58% | -1.443% |
AVDE Avantis International Equity ETF | 70,736 | $4.64M | $6.42M | - | $1.79M | 38.53% | +1.023% |
AVEM Avantis Emerging Markets Equity ETF | 59,352 | $4.2M | $5.33M | - | $1.13M | 26.91% | -0.675% |
AVGO Broadcom Inc. | 1,549 | $473,892.43 | $523,329.65 | - | $49,437.22 | 10.43% | -1.882% |
AVUS Avantis U.S. Equity ETF | 110,978 | $11.09M | $14.42M | - | $3.32M | 29.96% | +0.112% |
AVY Avery Dennison Corporation | 2,006 | $401,054.44 | $354,440.14 | - | -$46,614.3 | -11.62% | +0.461% |
AZN AstraZeneca PLC American Depositary Shares | 1,056 | $208,213.62 | $175,549.44 | - | -$32,664.18 | -15.69% | -0.264% |
BAC Bank of America Corporation | 4,852 | $251,564.09 | $254,608.7 | - | $3,044.61 | 1.21% | +1.499% |
BND Vanguard Total Bond Market Index Fund | 4,770 | $345,606.85 | $337,995.52 | - | -$7,611.33 | -2.2% | +0.069% |